Mersana Therapeutics (MRSN) Set to Announce Earnings on Thursday

→ Your $200 account credit is about to expire (From MarketBeat) (Ad)

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) will be announcing its earnings results before the market opens on Thursday, May 9th. Analysts expect Mersana Therapeutics to post earnings of ($0.18) per share for the quarter. Parties interested in listening to the company's conference call can do so using this link.

Get Mersana Therapeutics alerts:

Mersana Therapeutics (NASDAQ:MRSN - Get Free Report) last announced its quarterly earnings data on Wednesday, February 28th. The company reported ($0.16) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.16). The company had revenue of $10.70 million for the quarter, compared to analyst estimates of $22.59 million. Mersana Therapeutics had a negative return on equity of 282.36% and a negative net margin of 465.80%. The firm's revenue for the quarter was down 27.1% on a year-over-year basis. During the same quarter last year, the firm posted ($0.44) EPS. On average, analysts expect Mersana Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Mersana Therapeutics Price Performance

Shares of NASDAQ MRSN traded up $0.10 during mid-day trading on Friday, reaching $3.46. The company's stock had a trading volume of 1,188,670 shares, compared to its average volume of 2,153,765. The stock has a 50-day moving average of $4.35 and a two-hundred day moving average of $3.02. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.36 and a current ratio of 3.36. The stock has a market capitalization of $419.70 million, a P/E ratio of -2.40 and a beta of 1.61. Mersana Therapeutics has a 1-year low of $0.80 and a 1-year high of $9.62.

Ad DTI

weirdest stock market marches on

For the last few months, Graham Lindman has been urging investors to ignore virtually every stock on the exchange and only focus on the handful of “Apex Stocks” that produce all the wealth. And he sure seems to be right! Because while we’re in an extremely bullish market, it’s not because most companies are doing that well. It’s because a handful of wealth generating juggernauts are yanking the market to all time highs. That’s why this headline called it the “Weirdest bull market”

Graham is hosting a “tell all” workshop about his Apex Indicator here

Wall Street Analysts Forecast Growth

A number of research firms have commented on MRSN. Guggenheim upgraded shares of Mersana Therapeutics from a "neutral" rating to a "buy" rating and set a $7.00 price objective for the company in a report on Thursday, February 29th. BTIG Research raised Mersana Therapeutics from a "neutral" rating to a "buy" rating and set a $6.00 target price for the company in a research note on Thursday, February 29th. Truist Financial raised shares of Mersana Therapeutics from a "hold" rating to a "buy" rating and set a $9.00 price target on the stock in a research report on Thursday, February 29th. Robert W. Baird raised their price objective on shares of Mersana Therapeutics from $1.00 to $5.00 and gave the stock a "neutral" rating in a research report on Thursday, February 29th. Finally, Wedbush upgraded shares of Mersana Therapeutics from a "neutral" rating to an "outperform" rating and boosted their target price for the company from $2.00 to $7.00 in a report on Thursday, February 29th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, Mersana Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.29.

Check Out Our Latest Stock Analysis on MRSN

Mersana Therapeutics Company Profile

(Get Free Report)

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

Should you invest $1,000 in Mersana Therapeutics right now?

Before you consider Mersana Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mersana Therapeutics wasn't on the list.

While Mersana Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report